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Using Adverse Events in a Tuberculosis Trial to Describe the Tolerability of 
Standard Therapy 
 
 
Introduction and Objectives 
 
The current standard treatment for pulmonary tuberculosis (TB) has been in use 
for several decades and the major risks associated with each of the four drugs 
(HRZE) are well recognised. However, large prospective trials with regular 
review and documentation of adverse events while taking HRZE are lacking.  
 
We used the incidence of grade 3 and 4 adverse events (AEs) and serious 
adverse events (SAEs) in patients taking HRZE in the REMoxTB trial to 
investigate the overall tolerability of the regimen.  
 
Methods 
 
Grade 3 or 4 AEs and SAEs (of any grade) for patients taking standard TB 
therapy were analysed. Events were labelled as occurring in the intensive phase, 
continuation phase or in follow-up (up to 18 months after enrolment). ANOVA 
and chi-square testing was used to test for significant differences in the 
incidence of events across the treatment phases. Logistic regression was used to 
investigate associations between baseline characteristics and on-treatment SAEs 
and withdrawal from treatment, death or relapse/treatment failure. 
 
Results 
 
201 (31.5%) of 639 patients taking standard therapy experienced grade 3/4 AEs 
or SAEs during treatment. AEs, SAEs, and withdrawals from treatment occurred 
most frequently in the intensive phase (see Table). Of 116 SAEs reported 84 
(72.4%) improved or resolved and were most commonly respiratory (16.4%), 
gastrointestinal (6.9%), and infection (5.2%) related. There were 10 deaths in 
follow-up due to suicide, trauma, TB relapse, and acute illness. Logistic 
regression detected a significant association between on-treatment SAEs and 
withdrawal (p<0.001) or death (p<0.001), but not relapse/treatment failure 
(p=0.611). HIV-positive status (OR 4.25, p=0.016) and lower baseline weight (OR 
1.46, p=0.023) were associated with the reporting of on-treatment SAEs. 
 
Discussion 
 
AEs and SAEs were predominantly reported in the intensive phase, probably due 
to a combination of TB and effects of medication. However most deaths occurred 
in follow-up and were unrelated, emphasising the impact that social 
circumstances have on TB patients. The lack of significant association between 
SAEs during treatment and relapse/treatment failure provides reassurance that 
a complicated treatment period can end with successful treatment of TB. The 
association between SAEs on treatment and lower weights at baseline and HIV 
infection reinforces the need to monitor these patients closely. 
 
 Intensive  
Phase 
(Month 0-2) 
 
n=639 
Continuation 
Phase 
(Month 3-6) 
 
n= 596 
Follow Up 
Phase 
(Month 7-
18) 
n= 569 
 
P value 
No of Grade 3 AEs  
Reported 
66 31 19 *** 
No. Grade 4 AEs  
Reported 
19 6 3 *** 
System Organ Class of  
Reported Grade 3 & 4 AEs 
    
 Musculoskeletal 14 7 0 0.102 
Metabolism & 
Nutrition 
11 0 6 0.006 
General Disorders 7 3 1 0.838 
No of Grade 3 or 4 AEs  
per Patient 
    
 0 578 574 554  
<0.001  1 49 18 9 
 2 9 2 4 
 ≥3 3 2 2 
No of Patients  
with ≥1 SAE 
(Considered Related) 
32 
 
(21) 
18 
 
(6) 
20 
 
(2) 
0.168 
Mean No of SAEs  
per Patient  
1.78 1.39 1.60 0.092 
No of Withdrawals  
 
38 26 1 <0.001 
No of Deaths  
 
5 1 10 0.014 
 
